View Item 

Show simple item record

Identification of blood‐protein carriers of the CA 19‐9 antigen and characterization of prevalence in pancreatic diseases

dc.contributor.authorYue, Tingtingen_US
dc.contributor.authorPartyka, Katieen_US
dc.contributor.authorMaupin, Kevin A.en_US
dc.contributor.authorHurley, Mary C.en_US
dc.contributor.authorAndrews, Philipen_US
dc.contributor.authorKaul, Karenen_US
dc.contributor.authorMoser, A. Jamesen_US
dc.contributor.authorZeh, Herberten_US
dc.contributor.authorBrand, Randall E.en_US
dc.contributor.authorHaab, Brian B.en_US
dc.date.accessioned2011-11-10T15:39:32Z
dc.date.available2012-11-02T18:56:52Zen_US
dc.date.issued2011-09en_US
dc.identifier.citationYue, Tingting; Partyka, Katie; Maupin, Kevin A.; Hurley, Mary; Andrews, Philip; Kaul, Karen; Moser, A. James; Zeh, Herbert; Brand, Randall E.; Haab, Brian B. (2011). "Identification of blood‐protein carriers of the CA 19‐9 antigen and characterization of prevalence in pancreatic diseases." PROTEOMICS 11(18): 3665-3674. <http://hdl.handle.net/2027.42/87153>en_US
dc.identifier.issn1615-9853en_US
dc.identifier.issn1615-9861en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/87153
dc.description.abstractThe current best serum marker for pancreatic cancer, CA 19‐9, detects a carbohydrate antigen on multiple protein carriers. Better knowledge of the protein carriers of the CA 19‐9 antigen in various disease states may lead to improved diagnostic tests. To identify proteins that carry the CA 19‐9 antigen, we immunoprecipitated the CA 19‐9 antigen from pooled sera and identified the associated proteins using MS. Among the high‐confidence identifications, we confirmed the presence of the CA 19‐9 antigen on Apolipoprotein B‐100 by antibody arrays and Western blot and on kininogen, ARVCF, and Apolipoprotein E by antibody arrays. We characterized the frequency and levels of the CA 19‐9 antigen on the four proteins across various patient groups (pancreatic cancer, pancreatitis, and healthy controls) using antibody arrays. Nearly, 10–25% of the subjects showed elevations of the antigen on each protein, but the elevations were not associated with disease state or total CA 19‐9 levels. These results contribute to our knowledge of the carrier proteins of an important functional glycan and the rate at which the glycan is displayed. This work also demonstrates a strategy for using the complementary methods of MS and antibody microarrays to identify protein carriers of glycans and assess the diagnostic value of measuring glycans on individual proteins.en_US
dc.publisherWILEY‐VCH Verlagen_US
dc.subject.otherAntibody Arraysen_US
dc.subject.otherCA 19‐9en_US
dc.subject.otherGlycoproteomicsen_US
dc.subject.otherGlycosylationen_US
dc.subject.otherPancreatic Canceren_US
dc.titleIdentification of blood‐protein carriers of the CA 19‐9 antigen and characterization of prevalence in pancreatic diseasesen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbsecondlevelChemical Engineeringen_US
dc.subject.hlbsecondlevelChemistryen_US
dc.subject.hlbsecondlevelMaterials Science and Engineeringen_US
dc.subject.hlbsecondlevelMolecular, Cellular and Developmental Biologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelEngineeringen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan School of Medicine, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherVan Andel Research Institute, Grand Rapids, MI, USAen_US
dc.contributor.affiliationotherEvanston Northwestern Healthcare, Evanston, IL, USAen_US
dc.contributor.affiliationotherUniversity of Pittsburgh, Pittsburgh, PA, USAen_US
dc.contributor.affiliationotherVan Andel Research Institute, 333 Bostwick NE, Grand Rapids, MI 49503, USA Fax: +1‐616‐234‐5269en_US
dc.identifier.pmid21751362en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/87153/1/pmic_201000827_sm_SupplInfo.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/87153/2/3665_ftp.pdf
dc.identifier.doi10.1002/pmic.201000827en_US
dc.identifier.sourcePROTEOMICSen_US
dc.identifier.citedreferenceMaitra, A., Hruban, R. H., Pancreatic cancer. Ann. Rev. Pathol. 2008, 3, 157 – 188.en_US
dc.identifier.citedreferenceHruban, R. H., Adsay, N. V., Molecular classification of neoplasms of the pancreas. Human Pathol. 2009, 40, 612 – 623.en_US
dc.identifier.citedreferenceKloppel, G., Adsay, N. V., Chronic pancreatitis and the differential diagnosis versus pancreatic cancer. Arch. Pathol. Lab. Med. 2009, 133, 382 – 387.en_US
dc.identifier.citedreferenceLudwig, J. A., Weinstein, J. N., Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 2005, 5, 845 – 856.en_US
dc.identifier.citedreferenceEtzioni, R., Urban, N., Ramsey, S., McIntosh, M. et al., The case for early detection. Nat. Rev. Cancer 2003, 3, 243 – 252.en_US
dc.identifier.citedreferencePleskow, D. K., Berger, H. J., Gyves, J., Allen, E. et al., Evaluation of a serologic marker, CA19‐9, in the diagnosis of pancreatic cancer. Ann. Intern. Med. 1989, 110, 704 – 709.en_US
dc.identifier.citedreferenceKo, A. H., Hwang, J., Venook, A. P., Abbruzzese, J. L. et al., Serum CA19‐9 response as a surrogate for clinical outcome in patients receiving fixed‐dose rate gemcitabine for advanced pancreatic cancer. Br. J. Cancer 2005, 93, 195 – 199.en_US
dc.identifier.citedreferenceRitts, R. E., Jr., Nagorney, D. M., Jacobsen, D. J., Talbot, R. W., Zurawski, V. R., Jr., Comparison of preoperative serum CA19‐9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease. Pancreas 1994, 9, 707 – 716.en_US
dc.identifier.citedreferenceGoonetilleke, K. S., Siriwardena, A. K., Systematic review of carbohydrate antigen (CA 19‐9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur. J. Surg. Oncol. 2007, 33, 266 – 270.en_US
dc.identifier.citedreferenceAkagi, J., Takai, E., Tamori, Y., Nakagawa, K., Ogawa, M., CA19‐9 epitope a possible marker for MUC‐1/Y protein. Int. J. Oncol. 2001, 18, 1085 – 1091.en_US
dc.identifier.citedreferenceYue, T., Goldstein, I. J., Hollingsworth, M. A., Kaul, K. et al., The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody‐lectin sandwich arrays. Mol. Cell. Proteomics 2009, 8, 1697 – 1707.en_US
dc.identifier.citedreferenceHollingsworth, M. A., Swanson, B. J., Mucins in cancer: protection and control of the cell surface. Nat. Rev. Cancer 2004, 4, 45 – 60.en_US
dc.identifier.citedreferenceChen, S., LaRoche, T., Hamelinck, D., Bergsma, D. et al., Multiplexed analysis of glycan variation on native proteins captured by antibody microarrays. Nat. Methods 2007, 4, 437 – 444.en_US
dc.identifier.citedreferenceHaab, B. B., Antibody‐lectin sandwich arrays for biomarker and glycobiology studies. Exp. Rev. Proteomics 2010, 7, 9 – 11.en_US
dc.identifier.citedreferenceForrester, S., Kuick, R., Hung, K. E., Kucherlapati, R., Haab, B. B., Low‐volume, high‐throughput sandwich immunoassays for profiling plasma proteins in mice: identification of early‐stage systemic inflammation in a mouse model of intestinal cancer. Mol. Oncol. 2007, 1, 216 – 225.en_US
dc.identifier.citedreferenceZeng, Z., Hincapie, M., Haab, B. B., Hanash, S. et al., The development of an integrated platform to identify breast cancer glycoproteome changes in human serum. J. Chromatogr. A 2010, 1217, 3307 – 3315.en_US
dc.identifier.citedreferenceYue, T., Haab, B. B., Microarrays in glycoproteomics research. Clin. Lab. Med. 2009, 29, 15 – 29.en_US
dc.identifier.citedreferenceWu, Y. M., Nowack, D. D., Omenn, G. S., Haab, B. B., Mucin glycosylation is altered by pro‐inflammatory signaling in pancreatic‐cancer cells. J. Proteome Res. 2009, 8, 1876 – 1886.en_US
dc.identifier.citedreferenceMahley, R. W., Innerarity, T. L., Rall, S. C. Jr., Weisgraber, K. H., Plasma lipoproteins: apolipoprotein structure and function. J. Lipid Res. 1984, 25, 1277 – 1294.en_US
dc.identifier.citedreferenceCho, W., Jung, K., Regnier, F., Use of glycan targeting antibodies to identify cancer‐associated glycoproteins in plasma of breast cancer patients. Anal. Chem. 2008, 80, 5286 – 5292.en_US
dc.identifier.citedreferenceLee, A., Chick, J. M., Kolarich, D., Haynes, P. A. et al., Liver membrane proteome glycosylation changes in mice bearing an extra‐hepatic tumour. Mol. Cell. Proteomics 2010.en_US
dc.identifier.citedreferenceThompson, S., Kelly, C. A., Griffiths, I. D., Turner, G. A., Abnormally‐fucosylated serum haptoglobins in patients with inflammatory joint disease. Clin. Chim. Acta; Int. J. Clin. Chem. 1989, 184, 251 – 258.en_US
dc.identifier.citedreferenceThompson, S., Dargan, E., Turner, G. A., Increased fucosylation and other carbohydrate changes in haptoglobin in ovarian cancer. Cancer Lett. 1992, 66, 43 – 48.en_US
dc.identifier.citedreferenceOkuyama, N., Ide, Y., Nakano, M., Nakagawa, T. et al., Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int. J. Cancer 2006, 118, 2803 – 2808.en_US
dc.identifier.citedreferenceYoung, S. G., Recent progress in understanding apolipoprotein B. Circulation 1990, 82, 1574 – 1594.en_US
dc.identifier.citedreferenceKane, J. P., Hardman, D. A., Paulus, H. E., Heterogeneity of apolipoprotein B: isolation of a new species from human chylomicrons. Proc. Natl. Acad. Sci. USA 1980, 77, 2465 – 2469.en_US
dc.identifier.citedreferenceLi, A. C., Glass, C. K., The macrophage foam cell as a target for therapeutic intervention. Nat. Med. 2002, 8, 1235 – 1242.en_US
dc.identifier.citedreferenceGroux‐Degroote, S., Krzewinski‐Recchi, M. A., Cazet, A., Vincent, A. et al., IL‐6 and IL‐8 increase the expression of glycosyltransferases and sulfotransferases involved in the biosynthesis of sialylated and/or sulfated Lewisx epitopes in the human bronchial mucosa. Biochem. J. 2008, 410, 213 – 223.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
pmic_201000827_sm_SupplInfo.pdf
Size:
1.413MB
Format:
PDF
View/Open
Name:
3665_ftp.pdf
Size:
453.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.